GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2013 by GlaxoSmithKline
Sponsor:
Collaborator:
Human Genome Sciences Inc., a GSK Company
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01345253
First received: April 28, 2011
Last updated: July 11, 2013
Last verified: June 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 2015
  Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)